Cisplatin resistance-related multi-omics differences and the establishment of machine learning models

OBJECTIVES: Platinum-based chemotherapies are currently the first-line treatment of non-small cell lung cancer. This study will improve our understanding of the causes of resistance to cisplatin, especially in lung adenocarcinoma (LUAD) and provide a reference for therapeutic decisions in clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Qihai, Chen, Zhencong, Hu, Zhengyang, Huang, Yiwei, Liang, Jiaqi, Bi, Guoshu, Bian, Yunyi, Zhao, Mengnan, Zhan, Cheng, Lin, Zongwu, Wang, Qun, Tan, Lijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004122/
https://www.ncbi.nlm.nih.gov/pubmed/35410350
http://dx.doi.org/10.1186/s12967-022-03372-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004122/
https://www.ncbi.nlm.nih.gov/pubmed/35410350
http://dx.doi.org/10.1186/s12967-022-03372-0

Ejemplares similares